Elaine Lima
Pomona, CANPI 1215688668
Payments from drug & device makers
Across 163 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AbbVie$369
- AstraZeneca$365
- Novo Nordisk$347
- Lilly USA, LLC$310
- GSK$260
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,813100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 45 | $1,132 |
| AbbVie | 23 | $369 |
| AstraZeneca | 9 | $365 |
| Novo Nordisk | 24 | $347 |
| Lilly USA, LLC | 12 | $310 |
| GSK | 8 | $260 |
| Bayer | 9 | $250 |
| Otsuka America Pharmaceutical, Inc. | 4 | $110 |
| Teva Pharmaceuticals USA, Inc. | 4 | $103 |
| Sumitomo Pharma America, Inc. | 4 | $101 |
| Kowa Pharmaceuticals America, Inc. | 4 | $79 |
| Johnson & Johnson | 3 | $72 |
| Pfizer | 3 | $64 |
| Idorsia Pharmaceuticals US Inc | 1 | $61 |
| Dexcom, Inc. | 3 | $46 |
| Exact Sciences | 2 | $45 |
| Corium, LLC | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Insulet Corporation | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $54,846 |
| Repatha SureclickEvolocumab | 37 | $24,463 |
| JardianceEmpagliflozin | 18 | $19,464 |
| JanuviaSitagliptin Phosphate | 16 | $12,636 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $9,019 |
| MyrbetriqMirabegron | 11 | $8,824 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $7,198 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 15 | $3,900 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,765 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,330 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 77 | $1,385 |
| Atorvastatin Calcium | 93 | $827 |
| Testosterone Cypionate | 13 | $754 |
| Omeprazole | 64 | $751 |
| Fluticasone Propionate | 57 | $616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $347 | $54,84646 claims |
| Boehringer IngelheimJardiance | $15 | $19,46418 claims |
| GSKTrelegy Ellipta | $260 | $9,01912 claims |
| Lilly USA, LLCHumulin 70-30 | $310 | $3,90015 claims |
| AstraZenecaSymbicort | $365 | $2,76512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Californiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.